Antimicrobial resistance and novel therapies
Managing 'untreatable' infections
,
Antimicrobial resistance (AMR) threatens population health in low and middle income countries and indigenous Australians, but also major medical advances in surgery, cancer, transplantation, and intensive care. Our research is looking at approaches to combat the spectre of potentially ‘untreatable’ infections (bacterial, fungal and viral).
Pharmacokinetics (PK) and pharmacodynamics (PD) are two interconnected aspects of how drugs interact with the body.
By studying PK and PD, researchers can optimise drug formulations, design effective dosing regimens, and predict outcomes in different populations, ultimately ensuring safety and efficacy in clinical applications.
These fields are essential for translating experimental findings into viable therapeutic solutions.
Phage therapy is a medical treatment that uses bacteriophages—viruses that specifically infect and kill bacteria—as an alternative or complement to antibiotics for combating bacterial infections.
This approach leverages the natural ability of phages to target specific bacterial strains without harming beneficial bacteria or human cells, making it a precision tool against infections.
Working closely with the Centre for Drug Discovery Innovation, we are working to tackle the spread of infectious diseases and overcome drug resistance by discovering new targets and lead compounds for Gram negative bacteria, tuberculosis and fungal infections.
Mailing address
Westmead Hospital
Level 5, Block K
Westmead NSW 2145
